News | Wearables | June 14, 2019

Bardy Diagnostics Wins MedTech Breakthrough Award for Best New Diagnostic Technology

Carnation Ambulatory Monitor selected out of more than 3,500 nominations for “disrupting decades of old practice and technology for cardiac diagnostics and monitoring"

Bardy Diagnostics Wins MedTech Breakthrough Award for Best New Diagnostic Technology

June 14, 2019 — Bardy Diagnostics Inc. announced that its Carnation Ambulatory Monitor (CAM) was recognized with the “Best New Diagnostic Technology” award in the 2019 MedTech Breakthrough Awards Program. MedTech Breakthrough is an independent organization that recognizes the top companies and solutions in the global health and medical technology market. BardyDx earned the distinction for its P-wave centric ambulatory cardiac patch monitoring and arrhythmia detection technology.

Reliably detecting and recording the P-wave, a small amplitude signal of the electrocardiogram (ECG) originating in the atrium, is essential to accurate arrhythmia diagnosis and the determination of appropriate medical or procedural intervention.

The MedTech Breakthrough Awards program is the premier awards and recognition platform founded to recognize the medical and health technology innovators, leaders and visionaries from around the world. The program evaluates and recognizes breakthrough solutions and companies in a range of categories, including Medical Devices, mHealth, Robotics, TeleHealth, Patient Engagement, Electronic Health Records (EHR), Healthcare Security, Medical Data and more. This year's program attracted more than 3,500 nominations from over 15 different countries throughout the world that were evaluated by an independent panel of experts within the medtech industry, with the winning products and companies selected based on a variety of considerations, including innovation, design and user experience.

"BardyDx's non-invasive P-wave centric CAM patch is disrupting decades of old practice and technology for cardiac diagnostics and monitoring," said James Johnson, managing director, MedTech Breakthrough. "CAM represents a true digital health breakthrough and we are thrilled to recognize the company with a 2019 MedTech Breakthrough Award in recognition of their outstanding success and innovation in the digital health space."

Last month, BardyDx was named both the winner of the 2019 Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring and the winner of the 2019 GeekWire Award in the Hardware of the Year category. Also, BardyDx was recently named the winner of the Impact Pediatric Health Competition hosted by the nation's leading pediatric healthcare institutions at SXSW 2019 for the CAM's pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was also selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.

The full list of the 2019 MedTech Breakthrough Award winners can be found here.

For more information: www.bardydx.com

Related Content

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc.
Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...